These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Prophylactic action of polyvinylpyridine-N-oxide of different molecular weights on experimental silicosis]. Bogdanskaia NI, Tolgskaia MS. Gig Sanit; 1973 Apr; 38(4):102-4. PubMed ID: 4731236 [No Abstract] [Full Text] [Related]
3. [Treatment of experimental silicosis with polyvinyl-pyridine-N-oxide]. Bogdanskaia NI. Gig Tr Prof Zabol; 1973 May; 17(5):22-5. PubMed ID: 4771393 [No Abstract] [Full Text] [Related]
4. [Hydroxyproline content in the peptide makeup of the lung tissue of animals with experimental silicosis]. Rodkina BS. Ukr Biokhim Zh; 1974 May; 46(3):393-7. PubMed ID: 4836947 [No Abstract] [Full Text] [Related]
5. [Regression of experimental silicotic granuloma under the influence of polyvinylpyridin-N-oxide]. Grundmann E, Schlipköter HW. Verh Dtsch Ges Pathol; 1969 May; 53():367-70. PubMed ID: 4191095 [No Abstract] [Full Text] [Related]
6. [Clinical studies on the elimination of hydroxyproline during treatment of silicosis in man with polyvinyl-pyridine-N-oxide (author's transl)]. Schlipköter H, Grünspan M, Dehnen W, Mallner B. Infection; 1974 May; 2(1):25-8. PubMed ID: 4598261 [No Abstract] [Full Text] [Related]
7. [Possible paths for influencing the mechanism of experimental silicosis]. Shnaĭdman IM, Raĭkhlin NT. Biull Eksp Biol Med; 1973 Jun; 75(6):27-30. PubMed ID: 4149770 [No Abstract] [Full Text] [Related]
8. [Behavior of the human liver during silicosis therapy using polyvinylpyridine-N-oxide (PVNO)]. Haas P, Huber W. Beitr Silikoseforsch Pneumokoniose; 1971 Jun; 23(3):91-100. PubMed ID: 5171411 [No Abstract] [Full Text] [Related]
9. [Antisilicotic properties of polyvinylpyridine-N-oxide with a different molecular weight]. Dubovik BV, Shadurskiĭ KS, Etlis VS, Lushnikova GA, Shevchuk AS. Farmakol Toksikol; 1971 Jun; 34(3):352-7. PubMed ID: 5568700 [No Abstract] [Full Text] [Related]
10. [Determination of serum polyvinylpyridine-N-oxide after intravenous administration in silicosis patients]. Grünspan M, Antweiler H, Marcic I. Beitr Silikoseforsch Pneumokoniose; 1971 Jun; 23(3):101-13. PubMed ID: 5171408 [No Abstract] [Full Text] [Related]
14. [Animal experimental fundamentals in the medicinal prevention of silicosis using polyvinylpyridine-N-oxide (P204)]. Pott F, Schlipköter HW, Brockhaus A. Dtsch Med Wochenschr; 1968 Dec 20; 93(51):2479-82. PubMed ID: 5724499 [No Abstract] [Full Text] [Related]